Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
OBJECTIVES
Women with recurrent high-grade neuroendocrine cervical cancer have few effective treatment options. The aim of this study was to identify potential therapeutic targets for women with this disease.


METHODS
Specimens from patients with high-grade neuroendocrine carcinomas of the cervix were identified from pathology files at MD Anderson Cancer Center. Immunohistochemical stains for PD-L1 (DAKO, clone 22-C3), mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), somatostatin, and Poly (ADP-ribose) polymerase (PARP) were performed on sections from formalin-fixed paraffin-embedded tissue blocks. Nuclear PARP-1 staining was quantified using the H-score with a score of <40 considered low, 40-100 moderate, and ≥100 high.


RESULTS
Forty pathologic specimens from patients with high-grade neuroendocrine carcinomas of the cervix were examined (23 small cell, 5 large cell, 3 high-grade neuroendocrine, not otherwise specified, and 9 mixed). The mean age of the cohort was 43 years and the majority of patients (70%) were identified as white non-Hispanic. All 28 (100%) samples tested stained for mismatch repair proteins demonstrated intact expression, suggesting they were microsatellite stable tumors. Of the 31 samples tested for PD-L1 expression, only two (8%) of the 25 pure high-grade neuroendocrine carcinomas were positive whereas three (50%) of the six mixed carcinoma tumors tested positive. Of the 11 small cell specimens tested for PARP-1, 10 (91%) showed PARP expression with six (55%) demonstrating high expression and four (36%) showing moderate expression. Somatostatin staining was negative in 18 of 19 small cell cases (95%).


CONCLUSIONS
Pure high-grade neuroendocrine cervical carcinomas were microsatellite stable and overwhelmingly negative for PD-L1 expression. As the majority of tumors tested expressed PARP-1, inclusion of PARP inhibitors in future clinical trials may be considered.
['Carroll|Matthew Ryan|MR|0000-0002-3393-9124', 'Ramalingam|Preetha|P|', 'Salvo|Gloria|G|0000-0002-1753-1778', 'Fujimoto|Junya|J|', 'Solis Soto|Luisa Maren|LM|', 'Phoolcharoen|Natacha|N|', 'Hillman|Robert Tyler|RT|', 'Cardnell|Robert|R|', 'Byers|Lauren|L|', 'Frumovitz|Michael|M|']
D000328:Adult D018278:Carcinoma, Neuroendocrine D005260:Female D006801:Humans D007167:Immunotherapy D060787:Neoplasm Grading D000067856:Poly(ADP-ribose) Polymerase Inhibitors D002583:Uterine Cervical Neoplasms
cervical cancer pathology neuroendocrine tumors